TREOS Bio today announced the publication in Journal of Clinical Oncology - Oncology Advances of results from OBERTO-201 (NCT05130060), a Phase 1b study evaluating PolyPEPI1018, an off-the-shelf multi ...

Based on these data, iSCIB1+ has been selected for future development expanding the addressable patients to around 80% of late-stage melanoma patients and with longer patent life. Development plans ...

Scancell Holdings reported strong phase two results for its Immunobody iSCIB1+ cancer immunotherapy on Friday, showing ...

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today ...

Background Globally, an estimated 296 million individuals live with chronic hepatitis B virus (HBV) infection, carrying ...

Finding the perfect tech gifts can be tricky, but The AP has put together a quick guide to help. For gamers, the Nintendo ...

Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell ...

Findings suggest maternal T1D exposure leads to protective epigenetic alterations in children, influencing immune response ...

From chemotherapy to immunotherapy, medical science has rewritten the story of survival and hope for blood cancer patients in ...

GEN2 was evaluated in adult patients with advanced solid tumors in an intravenous dose escalation Phase 1 study GEN2 is well-tolerated, with no Dose Limiting Toxicity or treatment-related ...